KMT2A and acute myeloid leukemia: Overall, these results validate findings of the CRISPR screen by demonstrating that combined targeting with SNDX-50469 and agents that target CBP/EP300, MOZ or KDM1A, versus each agent alone, exerts greater lethal effects against AML cells with MLL1-r or mtNPM1.